Recherche Fr menu ClientConnect
5 premiers résultats de la recherche Voir tous les résultats Recherche avancée
Recherches les plus fréquentes
Pages les plus visitées
    Référence: 20170327
    Date de publication: 28 juin 2017

    Promoteur – Intermédiaire Financier




    The operation concerns the financing of the promoter's capital expenditure aimed at increasing production capacity for injectable anti-cancer drugs as well as research, development and innovation (RDI) expenses over the period 2017-2019.


    The project is expected to support the growth of the group and the development of new anti-cancer drugs through RDI activities. Moreover, the capital investments target the expansion of the installed production capacity at the promoter's existing manufacturing site.


    BSP Pharmaceuticals' established product leadership as a contract development manufacturing organisation (CDMO) in providing first-line chemotherapy drugs provides a foundation on which to build a further portfolio of oncological pharmaceuticals to be used in Europe and beyond.


    Montant BEI envisagé (montant approximatif)

    EUR 25 million

    Coût total (montant approximatif)

    EUR 55 million

    Aspects environnementaux

    All project activities are expected to be carried out in existing facilities without changing the already authorised scope and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending the EIA Directive 2011/92/EU.

    Passation des marchés

    The promoter is a private company not operating in the utilities sector and not having the status of a contracting entity. Thus it is not covered by EU rules on procurement.


    Signé - 9/05/2018

    Mots-clés correspondants

    Italie Industrie